Sarepta Therapeutics | SRPT - Assets


Sarepta Therapeutics reported $3.49B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 4.85B 285.64M Sep/2025
Amgen USD 90.14B 2.24B Sep/2025
Biogen USD 29.21B 877.3M Sep/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Gilead Sciences USD 58.53B 2.81B Sep/2025
Incyte USD 6.33B 509M Sep/2025
Insmed USD 2.36B 119.12M Sep/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Moderna USD 12.14B 125M Sep/2025
Neurocrine Biosciences USD 4.27B 375.9M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Tectonic Therapeutic USD 277M 18.31M Sep/2025
Ultragenyx Pharmaceutical USD 1.19B 115.82M Sep/2025
Vertex Pharmaceuticals USD 24.86B 825.6M Sep/2025